Relationship Between Long-Term Proton Pump Inhibitor Use and Serum Magnesium Levels: A Cross-Sectional Study
Abstract
Objective: The objective of this study is to determine the effect of long-term proton pump inhibitor use on serum magnesium levelsStudy Design: Descriptive cross-sectional study.Place and Duration of Study: The study was carried out at the Department of Medicine, Combined Military Hospital, Peshawar, Pakistan, from August 2022 to September 2022.Materials and Methods: Individuals from both genders were included with a minimum proton pump inhibitor usage of 1 year. Possible confounders, including patients with a history of smoking and alcohol use, GI disorders, hemodialysis dependence, and supplement use, were excluded. Data were summarized as frequencies and mean using a statistical package for social sciences software version 23. Standard deviation was calculated for quantitative variables.Results: Out of 398 patients included in the study, 72.3% (n=288) were males, and 27.7% (n=110) were females. The mean duration of proton pump inhibitor usage was 3.88±3.79 years. The mean serum magnesium level measured was 0.9548±0.14mmol/L. 2.3% (n=9) individuals had serum magnesium levels <0.7mmol/L, and all of them were using 40mg/day of either of the PPIs, while the remaining 97.7% (n=389) had a serum magnesium level of ≥0.7mmol/L.Conclusion: This study did not find any statistically significant impact of long-term proton pump inhibitor use on Serum Magnesium levels. Dietary magnesium may have a role in preventing this complication.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 398 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.